Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Dolutegravir Sodium Patent Expiration

Dolutegravir Sodium was first introduced by Viiv Healthcare Co in its drug Tivicay on Aug 12, 2013. Another drug containing Dolutegravir Sodium is Tivicay Pd.


Dolutegravir Sodium Patents

Given below is the list of patents protecting Dolutegravir Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Tivicay US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness Oct 05, 2027 Viiv Hlthcare
Tivicay US8129385

(Pediatric)

 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness Apr 05, 2028 Viiv Hlthcare
Tivicay US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates Dec 08, 2029 Viiv Hlthcare
Tivicay US9242986

(Pediatric)

 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates Jun 08, 2030 Viiv Hlthcare
Tivicay Pd US8129385 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness Oct 05, 2027 Viiv Hlthcare
Tivicay Pd US8129385

(Pediatric)

 Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness Apr 05, 2028 Viiv Hlthcare
Tivicay Pd US9242986 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates Dec 08, 2029 Viiv Hlthcare
Tivicay Pd US9242986

(Pediatric)

 Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates Jun 08, 2030 Viiv Hlthcare


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳